Sou Hu Cai Jing·2025-11-03 14:40Core Viewpoint - Rongchang Biopharmaceutical (688331) has engaged in a financial product agreement with SPD Bank, utilizing idle funds for investment, which is expected to yield a modest return [1] Group 1: Stock Performance - As of November 3, 2025, Rongchang Biopharmaceutical's stock closed at 97.9 yuan, down 1.23% from the previous trading day [1] - The stock opened at 99.26 yuan, reached a high of 99.99 yuan, and a low of 93.91 yuan, with a trading volume of 9.88 billion yuan and a turnover rate of 6.27% [1] Group 2: Financial Product Agreement - On November 3, 2025, the company signed an agreement with SPD Bank Yantai Branch to invest 400 million yuan in a principal-protected floating income financial product [1] - The product has a term of 25 days and an expected annualized return rate of 0.7%, 1.65%, or 1.85%, linked to the euro to US dollar exchange rate [1] - This transaction follows a similar agreement made on October 15, 2025, for 100 million yuan, necessitating combined disclosure due to the nature and timing of the transactions [1] Group 3: Compliance and Governance - The board of directors considers the terms of the transaction to be fair and in the overall interest of the company and its shareholders [1] - The transaction falls under the disclosure requirements of the listing rules, as one of the combined transactions exceeds 5% but is below 25% [1]